Compounds for Positron Emission Tomography

US2016287731A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2016287731-A1
Application numberUS-201415035936-A
CountryUS
Kind codeA1
Filing dateNov 13, 2014
Priority dateNov 14, 2013
Publication dateOct 6, 2016
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Described herein are compounds, compositions, and methods for diagnosing and/or monitoring pathogenic disease using positron emission tomography. Also described are conjugates of the formula B-L-P, wherein B is a radical of a targeting agent selected from vitamin receptor binding ligands (such as folate), PSMA binding ligands, or PSMA inhibitors; L is a divalent linker comprising aspartic acid, lysine, or arginine, and P is a radical of an imaging agent or radiotherapy agent, such as a radionuclide or radionuclide containing group, or a radical of a compound capable of binding a radionuclide, such as a metal chelating group.

First claim

Opening claim text (preview).

1 - 19 . (canceled) 20 . A conjugate of the formula B-L-P or a pharmaceutically acceptable salt thereof, wherein B is a radical of a targeting agent selected from vitamin receptor binding ligands, PSMA binding ligands, and PSMA inhibitors, L is a divalent linker, and P is a radical of an imaging agent or radiotherapy agent, such as a radionuclide or radionuclide containing group, or a precursor thereof, or a radical of a compound capable of binding a radionuclide or radionuclide containing group, such as a metal chelating group. 21 . The conjugate of claim 20 comprising folate-Asp, 22 . The conjugate of claim 20 comprising folate-Arg. 23 . The conjugate of claim 20 wherein the linker comprises a polypeptide comprising lysine, arginine, or aspartic acid, or a combination thereof. 24 . The conjugate of claim 20 wherein the linker does not include a diradical of the formula NH—(CH 2 ) 2 —NH, 25 . The conjugate of claim 20 comprising the formula or a derivative thereof comprising a chelated metal. 26 . The conjugate of claim 20 comprising folate-PEG. 27 . The conjugate of claim 26 comprising the formula or a derivative thereof comprising a chelated metal. 28 . The conjugate of claim 26 comprising the formula or a derivative thereof comprising a chelated metal. 29 . The conjugate of claim 20 wherein the targeting agent is a radical of a PSMA binding ligand or PSMA inhibitor. 30 . The conjugate of claim 29 comprising the formula where n is an integer selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; or where n is an integer selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; or where W is O or S. 31 . The conjugate of claim 29 wherein the linker comprises a polypeptide comprising phenylalanine, lysine, arginine, or aspartic acid, or a combination thereof. 32 . The conjugate of claim 29 comprising the formula or a derivative thereof comprising a chelated metal. 33 . The conjugate of claim 29 comprising the formula where n is an integer selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. 34 . The conjugate of claim 29 wherein the linker comprises the formula 35 . The conjugate of claim 29 wherein the linker comprises the formula 36 . The conjugate of claim 33 comprising the formula or a derivative thereof comprising a chelated metal. 37 . The conjugate of claim 20 , wherein the radionuclide is a positron-emitting radionuclide. 38 . The conjugate of claim 37 , wherein the positron-emitting radionuclide is selected from the group consisting of 89 Zr, 45 Ti, 51 Mn, 64 Cu, 61 Cu, 63 Zn, 82 Rb, 68 Ga, 66 Ga, 11 C, 13 N, 15 O, 124 I, 34 Cl, 18 F, and 19 F. 39 . The conjugate of claim 20 wherein the radionuclide is a radiotherapy agent.

Assignees

Inventors

Classifications

  • Antineoplastic agents · CPC title

  • of the prostate · CPC title

  • Detection or diagnosis of diseases · CPC title

  • having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine · CPC title

  • conjugates with a carrier being an organic compounds · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2016287731A1 cover?
Described herein are compounds, compositions, and methods for diagnosing and/or monitoring pathogenic disease using positron emission tomography. Also described are conjugates of the formula B-L-P, wherein B is a radical of a targeting agent selected from vitamin receptor binding ligands (such as folate), PSMA binding ligands, or PSMA inhibitors; L is a divalent linker comprising aspartic acid,…
Who is the assignee on this patent?
Endocyte Inc, Purdue Research Foundation
What technology area does this patent fall under?
Primary CPC classification A61K51/0497. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Thu Oct 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).